Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans

What Was Tested

This randomized controlled trial paper looks at Vasopressin and CGRP (Calcitonin Gene-Related Peptide).

Who Took Part

According to the abstract, 12 men were involved.

PubMed indexes the participants as adults, men only.

In preliminary experiments, two procedures to measure the V1 vascular effects of AVP were assessed.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of Vasopressin, giving a reference point.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

In a second protocol, AVP was infused intra-arterially, and the changes in radial artery diameter and blood flow were measured.

What Was Measured

PubMed files the paper under topics including Antidiuretic Hormone Receptor Antagonists, Arginine Vasopressin, Calcitonin Gene-Related Peptide, Forearm, Hormone Antagonists, Indoles and Injections, Intra-Arterial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and CGRP (Calcitonin Gene-Related Peptide) in 12 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Vasopressin compound page and the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.